Bookmarks

AMPLE (AMyloid imaging for Phenotyping LEwy body dementia)

Population Size

0

People

Population Size statistic card

Years

2013

Years statistic card

Associated BioSamples

None/not available

Associated BioSamples statistic card

Geographic coverage

United Kingdom

Geographic coverage statistic card

Lead time

Data only
Lead time statistic card

Summary

The principle aim of AMPLE is to undertake amyloid PET imaging in Lewy Body Dementia (LBD) and Alzheimer's disease (AD) participants and investigate the distribution of amyloid burden in LBD relative to AD and controls at baseline. A further aim is to determine the relationship between amyloid levels at baseline, clinical features of the disease, other imaging changes and subsequent clinical course in follow up.  Primary analysis would divide LBD patients into high and low amyloid burden with pa

Documentation

All Participants: Age 60+. Sufficient English to carry out cognitive testing. Controls: MMSE greater than or equal to 26. Lewy Body/AD Dementia: MMSE greater than or equal to 12. Meet criteria for probable LBD/AD. If taking anti-cholinesterase drugs or memantine, stable for at least 3 months. Presence of reliable informant sufficient to provide information for informant rated scales.Concurrent major psychiatric illness (e.g. major depression). Severe physical illness or comorbidity that may limit ability to fully participate in study. Past history of excess alcohol intake. Past history of neurological illness including stroke. Contra-indications for MR or PET. Psychotropic medications which may significantly interfere with cognitive testing (anti- dementia drugs not an exclusion criteria). Controls: memory complaints or signs/ symptoms of dementia. Past history of Parkinson's disease. Psychotropic medications which may significantly interfere with cognitive testing (anti- dementia drugs not an exclusion criteria). Controls: memory complaints or signs/ symptoms of dementia. Past history of Parkinson's disease. Alzheimer's patients: Past history of Parkinson's disease. All Participants: Contra-indications for MR or PET imaging.Past history of excessive alcohol intake. Past history of other neurological illness including, but not limited to stroke, intracerebral pathology. Psychotropic and other medications which may significantly interfere with cognitive testing (including but not limited to sedative antidepressants, benzodiazepines except low when used as hypnotics, centrally acting anticholinergic drugs). Use of anti dementia drugs (eg anti-cholinesterase drugs or memantine) is not an exclusion criterion. A relevant history of severe drug allergy or hypersensitivity. Have ever participated in an experimental study with an amyloid targeting agent (e.g. anti-amyloid immunotherapy, or γ-secretase inhibitor) unless it can be documented that the subject received only placebo during the course of the trial. Receiving any investigational medications, or participation in a trial with investigational medications within the last 30 days. A radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session.

Dataset type

Health and disease, Imaging types, Omics

Dataset sub-type

Not applicable

Keywords

Provenance

Purpose of dataset collection

Study

Biological sample availability

None/not available

Structural Metadata

Details

Publishing frequency

Continuous

Version

1.0.0

Modified

17/02/2025

Coverage

Start date

02/04/2013

Time lag

Not applicable

Geographic coverage

United Kingdom

Minimum age range

60

Maximum age range

100

Follow-up

Unknown

Accessibility

Language

en

Alignment with standardised data models

OTHER

Controlled vocabulary

OTHER

Format

CSV

Data Access Request

Dataset pipeline status

Available

Access method category

TRE/SDE

Access service description

The Data Portal runs its analysis environment through a virtual desktop infrastructure accessible via VMWare software. By analysing the data in the virtual desktop environment you are working on DPUK's servers – meaning there is no physical transfer of data to researchers. The processing capacity enables you to work with large numbers of records and integrate these with the other data modalities that exist in the DPUK cohorts. This solution also offers researchers the freedom to conduct their analyses anywhere with an internet connection.

Data Controller

Newcastle university

Data Processor

Dementias Platform UK

Dataset Types: Health and disease, Imaging types, Omics


Collection Sources:

end of page